Karyopharm Therapeutics (KPTI)
(Real Time Quote from BATS)
$0.70 USD
0.00 (0.29%)
Updated Sep 24, 2024 10:04 AM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 61 - 80 ( 390 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Encouraging New Data for Xpovio in Combination With Jakafi in Myelofibrosis Published in ASCO Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 3 XPORT-MM-031 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive CHMP Opinion For Nexpovio (selinexor) in Refractory Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Initial Data From Study of Xpovio in Combination With Jakafi in MF to be Presented at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
1Q22 Earnings; CHMP Opinion Expected 2Q22; Looking to Myelofibrosis Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Phase 3 SIENDO Data Highlighted in Presentation at ESMO Virtual Plenary
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 4.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 25.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Another Study Required for FDA Submission of Xpovio in Endometrial Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The FDA Gives Selinexor a Siesta Based on SIENDO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q21 Results; Excellent Xpovio Phase 3 SIENDO Data; 2022 Catalysts Abound
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FDA Grants Orphan Drug Designation for Eltanexor in MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E